Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00826280 · ClinicalTrials.gov registry record · Phase 3
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 347
- Enrollment target
NCT00826280: Completed Phase 3 study, sponsored by Astellas Pharma.
NCT00826280 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 347 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00826280, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 347 participants
- Enrollment target
Study Summary
Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI
Primary Outcome
Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2. Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).
Interventions
- DRUG placebo
- DRUG regadenoson
- DRUG overencapsulated caffeine
- RADIATION technetium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2009-03-24 |
| Est. Completion | 2010-07-15 |
| Phase | Phase 3 |
What the finished NCT00826280 record still lists
NCT00826280 is an interventional study that assigns participants to a tested intervention. The registered 347 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00826280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00826280 about?
NCT00826280 is a clinical study titled "Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)". Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI
What is the current status of trial NCT00826280?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 347 participants. The study started on 2009-03-24. Estimated completion is 2010-07-15.
What interventions are being tested in trial NCT00826280?
The interventions under investigation include: placebo (DRUG), regadenoson (DRUG), overencapsulated caffeine (DRUG), technetium (RADIATION).
Who is sponsoring clinical trial NCT00826280?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00826280's enrollment target sits among peer trials
347 1048th of 2000 higher than 952 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
- NCT04877522 · 347 participants · Phase 4
Asciminib Roll-over Study
- NCT05834660 · 347 participants · NA
SAFETY-A for Promoting Equity in Suicide Prevention Outcomes in Schools
- NCT06963827 · 347 participants · Phase 3
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI